Press Releases

November 2021
Enterome to present significant progress with its OncoMimics™ pipeline at Jefferies London Healthcare Conference
Read more
November 2021
Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases
Read more
October 2021
Enterome to attend upcoming conferences
Read more
September 2021
Enterome highlights Microbiome publication describing sibofimloc’s novel mechanism of action for the treatment of Crohn’s disease
Read more
July 2021
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
Read more
July 2021
Enterome to present at upcoming investor conferences
Read more
June 2021
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
Read more
April 2021
Enterome to present at upcoming conferences
Read more
March 2021
Enterome receives FDA IND clearance for EO2463, an ‘OncoMimic’ based immunotherapy targeting liquid tumors
Read more

Subscribe to our press releases



January 2022
Kempen Life Sciences Virtual Crossover Conference
January 2022
JP Morgan 2022

Presentations and posters

Corporate presentations

3rd November 2021


Microbiome derived peptides stimulate strong immune response against tumor associated antigens and trigger in vivo tumor regression after vaccination
L. Chene, et al.

AACR 2019

Relevant Literature

*authored by Enterome

OncoMimics approach

A very high level of crossreactivity is an essential feature of the T-cell receptor
D. Mason
Immunology today, September 1998
Cross-reactivity of T cells and its role in the immune system
G. Petrova, et al.
Crit Rev Immunol., March 2012
Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire
V. l. Zarnitsyna, et al.
Front Immunology, December 2013
Why must T cells be cross-reactive?
A. Sewell, et al.
Nature Reviews Immunology, August 2012
Challenges in the development of effective peptide vaccines for cancer
C. Buteau, et al.
Mayo Clin Proc, April 2002
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
M. Sioud, et al.
Scandinavian journal of immunology, January 2018
Pre-existing heterologous T-cell immunity and neoantigen immunogenicity
Q. Leng, et al.
Clin Transl Immunology, March 2020
Effector and Memory T cell Responses to Commensal Bacteria
Y. Belkaid, et al.
Trends Immunology, June 2013

EndoMimics approach

Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein- based Drugs
S. Fetissov, et al.
Current Medicinal Chemistry, October 2017
Gut microbiota in human metabolic health and disease
Y. Fan, et al.
Nature Reviews Microbiology, September 2020
IL-10 produced by macrophages regulates epithelial integrity in the small intestine
T. Morhardt, et al.
Scientific reports, February 2019
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
W. Ouyang, et al.
Immunity, April 2019
Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease
Tomaro-Duchesneau, et al.
Scientific Reports, March 2020
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Yoon, et al.
Nature Microbiology, April 2021
Mapping interactions of microbial metabolites with human G-protein-coupled receptors
Colosimo, et al.
Cell, Host & Microbe, August 2019

Computational platform

*GeneMark-HM: improving gene prediction in DNA sequences of human microbiome
A. Lomsadze, et al.
NAR Genomics and Bioinformatics, June 2021
*Scalable workflow and reproductible data analysis for genomics
F. Strozzi, et al.
Methods in molecular biology, July 2019
*MSP-Miner-abundance-based reconstitution of microbial pan-genomes from shotgun metagenomic data
F. Onate, et al.
Bioinformatics, May 2019
*A unified catalog of 204,938 reference’ genomes from the human gut microbiome
A. Almeida, et al.
Nature biotechnology, July 2020
*Incorporating phylogenetic information in microbiome differential abundance studies has no effect on detection power and FDR control
A. Bichat, et al.
Frontiers in microbiology, April 2020
A metagenomic strategy for harnessing the chemical repertoire of the human microbiome
Sugimoto, et al.
Science, December 2019
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals
Asnicar, et al.
Nature Medicine, January 2021
*Impact of laparoscopic Roux-enY gastric bypass and sleeve gastrectomy on gut microbiota – a metagenomic comparative analysis
W. Farin, et al.
Surgery for obesity and related diseases, March 2020

Focus on inflammatory diseases

*Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease
G. Chevalier, et al.
Microbiome, August 2021
*Antimicrobial resistance profiles of adherent invasive Escherichia coli show increased resistance to B-lactams
M. Martinez-Medina, et al.
Antibiotics, May 2020
*Gut microbiota diversity is reduced in smokers with Crohn’s disease
J. Opstelten, et al.
Inflammatory bowel diseases, September 2016

Focus on the gut microbiome impact on human health

*The human gut microbiome as source of innovation for health: which physiological and therapeutic outcomes could we expect?
J. Doré, et al.
Therapy, February 2017

Enterome France

94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex